Dernière mise à jour :
26/03/2024
Antibiotique   Cefepime dihydrochloride  
Injectable
Collyre
Stabilité des solutions Stabilité en mélange Facteur influençant la stabilité Compatibilités Voie d’administration Bibliographie Pdf
   Structure chimique  

Noms commerciaux   Noms commerciaux     

Les noms commerciaux sont donnés à titre indicatif et la composition en excipients peut être différente selon les pays et selon les laboratoires

Aspime Vénézuela
Avipim Turquie
Axépim France
Baxypime Mexique
Cachepime Inde
Cefalospim Brésil
Cefemin Colombie
Cefepem Brésil
Cefepitax Brésil
Cepim Italie
Cepimex Italie
Forcetex Egypte
Maxcef Brésil
Maxipime Allemagne, Autriche, Belgique, Canada, Colombie, Espagne, Etats Unis d’Amérique, Finlande, Grèce, Hongrie, Italie, Luxembourg, Pérou, Pologne, Portugal, Suède, Turquie
Nebamix Pérou
Olpelinol Mexique
Pimcef Pérou
Pimerzen Mexique
Roxipime Turquie
Unisef Turquie
Vipefime Mexique
Bibliographie   Injectable   Bibliographie : Cefepime dihydrochloride  
Type Source
182 Revue Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
251 Revue Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
873 Revue Das Gupta V, Maswoswe J, Bailey RE.
Stability of cefepime hydrochloride dextrose in 5% dextrose injection and 0.9% sodium chloride injection.
Int J Pharm Compound 1997 ; 1: 435-436.
921 Revue Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1046 Revue Stewart JT, Maddox FC, Warren FW.
Stability of cefepime hydrochloride in polypropylene syringes.
Am J Health-Syst Pharm 1999 ; 56: 1134.
1068 Revue Stewart JT, Warren FW, Maddox FC.
Stability of cefepime hydrochloride in polypropylene syringes at -20°C, 4°C and 22-24°C.
Am J Health-Syst Pharm 1999 ; 56: 457-459.
1290 Revue Williamson JC, Volles DF, Lynch PLM, Rogers PD, Haverstick DM.
Stability of cefepime in peritoneal dialysis solution.
Ann Pharmacotherapy 1999 ; 33: 906-909.
1410 Revue Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1605 Revue Stewart JT, Maddox FC, Warren FW.
Stability of cefepime hydrochloride injection and metronidazole in polyvinyl chloride bags at 4°C and 22-24°C.
Hosp Pharm 2000 ; 35: 1057-1064.
1625 Revue Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1626 Revue Ling J, Das Gupta V.
Stability of cefepime hydrochloride after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use.
Int J Pharm Compound 2001 ; 5: 151-152.
1648 Revue Schlesser V, Hecq J-D, Vanbeckbergen D, Jamart J, Galanti LM.
Effect of freezing, long-term storage, and microwave thawing on the stability of cefepime in 5% dextrose infusion polyvinyl chloride bags.
Int J Pharm Compound 2002 ; 6: 391-394.
1673 Revue Rabouan-Guyon M, Guet AF, Courtois PY, Barthes DMC.
Stability study of cefepime in different infusion solutions.
Int J Pharm 1997 ; 154: 185-190.
1712 Revue Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1713 Revue Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 Revue Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1754 Revue Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1803 Revue Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1834 Revue Trissel LA, Xu QA.
Stability of cefepime hydrochloride in autodose infusion system bags.
Ann Pharmacotherapy 2003 ; 37, 6: 804-807.
1945 Revue Elwell RJ, Volino LR, Frye RF.
Stability of cefepime in icodextrin peritoneal dialysis solution.
Ann Pharmacotherapy 2004 ; 38: 2041-2044.
1982 Revue Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2042 Revue Viaene E, Chanteux H, Servais H, Mingeot-Leclerq MP, Tulkens PM.
Comparative stability studies of antipseudomonal ß-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units).
Antimicrob Agents Chemother 2002 ; 46: 2327-2332.
2046 Revue Sprauten PF, Beringer PM, Louie ST, Synold TW, Gill MA.
Stability and antibacterial activity of cefepime during continuous infusion.
Antimicrob Agents Chemother 2003 ; 47: 1991-1994.
2134 Revue Fubara JO, Notari RE.
Influence of pH, temperature and buffers on cefepime degradation kinetics and stability predictions in aqueous solutions.
J Pharm Sci 1998 ; 87, 12: 1572-1576.
2141 Revue Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM.
Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units.
J Antimicrob Chemother 2003 ; 51: 651-658.
2192 Revue Cochran BG, Sowinski KM, Fausel C, Overholser BR.
Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs.
Am J Health-Syst Pharm 2007 ; 64, 13: 1410-1414.
2231 Revue de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S.
Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.
J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2247 Revue Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
3254 Revue Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3385 Revue Raverdi V, Ampe E, Hecq JD, Tulkens PM.
Stability and compatibility of vancomycin for administration by continuous infusion.
J Antimicrob Chemother 2013 ; 68: 1179-1182.
3416 Revue Csaba M, Boddu,S.H.S , Churchwell M.D.
Physical compatibility of sodium citrate with alcohol and cefepime.
Am J Health-Syst Pharm 2013 ; 70: 932-937
3520 Laboratoire Cidomycin - Summary of product Chracteristics.
Sanofi 2011
3542 Revue Berti A.D, Hutson P.R, Schulz L.T, Webb A.P, Rose W.E.
Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion
Am J Health-Syst Pharm 2015 ; 72:390-395
3548 Laboratoire Cefepime (Maxipime®) - Summary of Product caracteristics.
Bristol Myers Squibb 2007
3549 Laboratoire Amikacine B Braun - Résumé des caractéristiques du produit.
B Braun 2012
3643 Laboratoire Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics
Sanofi 2015
3674 Laboratoire Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016
3827 Poster Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 Poster Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Poster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3879 Revue Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E.
Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures.
Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3948 Revue Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P .
Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation.
JPEN 2012 ;30. 416?424.
4055 Revue Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145 Revue Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4254 Revue D'Huart E, Vigneron J, Demoré B.
Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs
Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4326 Revue Curti C, Harti Souab K, Lamy E, Mathias F, Bornet C, Guinard B, Fersing C, Primas N, Albanèse J, Vanelle P.
Stability studies of antipyocyanic beta-lactam antibiotics used in continuous infusion.
Pharmazie 2019 ; 74: 357-362.
4411 Revue Wilder A.G, Foushee J.A, Fox L.M, Navalle J, Wright A.M, Greer M.A.
Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions.
Int J Pharm Compound 2020 ;24,3:238-241.
4434 Revue Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170.
4440 Revue Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M.
Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion.
Ann Nutr Metab 2018 ; 73: 227-233.
4465 Revue Foushee A, Meredith P, Fox Laura, Wilder A.
Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients.
Am J Health-Syst Pharm 2020 ;77,14:1144-1148
4521 Revue Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B.
Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit.
Pharmaceutical Technology in Hospital Pharmacy 2020
4528 Revue Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4634 Revue Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A.
Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy.
Antibiotics 2022 ;11,4: 458

  Mentions Légales